Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Erwan Le Dault

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Emerging Microbes & Infections|February 20, 2025
Lessons for medical countermeasure development from unforeseen outbreaksMarie Mura, Aurélie Trignol, Erwan Le Dault, et al.
Diagnostic Microbiology and Infectious Disease|August 3, 2021
Real-time next-generation sequencing on shell-vial culture to contribute to diagnosis of lymphatic tuberculosis: a case reportMadjid Morsli, Marc Faltot, Hélène Astier, et al.
Nature|July 30, 2020
Association of COVID-19 inflammation with activation of the C5a-C5aR1 axisJulien Carvelli, Olivier Demaria, Frédéric Vély, et al.
Critical Care Medicine|October 11, 2022
Avdoralimab (Anti-C5aR1 mAb) Versus Placebo in Patients With Severe COVID-19: Results From a Randomized Controlled Trial (FOR COVID Elimination [FORCE])Julien Carvelli, Ferhat Meziani, Jean Dellamonica, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Emerging Microbes & Infections|February 20, 2025
Lessons for medical countermeasure development from unforeseen outbreaksMarie Mura, Aurélie Trignol, Erwan Le Dault, et al.
Diagnostic Microbiology and Infectious Disease|August 3, 2021
Real-time next-generation sequencing on shell-vial culture to contribute to diagnosis of lymphatic tuberculosis: a case reportMadjid Morsli, Marc Faltot, Hélène Astier, et al.
Nature|July 30, 2020
Association of COVID-19 inflammation with activation of the C5a-C5aR1 axisJulien Carvelli, Olivier Demaria, Frédéric Vély, et al.
Critical Care Medicine|October 11, 2022
Avdoralimab (Anti-C5aR1 mAb) Versus Placebo in Patients With Severe COVID-19: Results From a Randomized Controlled Trial (FOR COVID Elimination [FORCE])Julien Carvelli, Ferhat Meziani, Jean Dellamonica, et al.
Pageof 1